TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34118255
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preparation in the MM canal)
Study: 32947474
Drug: Antithrombin supplementation
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin supplementation (treatment group)
Study: 34621054
Drug: PGT121 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121 at 3, 10 and 30 mg kg-1
Study: 34621054
Drug: PGT121 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121 at 30 mg kg-1
Study: 35267206
Drug: Mailed nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mailed nicotine replacement therapy (NRT) and Quitline support
Study: 34117385
Drug: Transconjunctival (Tconj)
Normalized name: Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transconjunctival (Tconj) local anaesthetic administration
Study: 34117385
Drug: Transcutaneous (Tskin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous (Tskin) local anaesthetic administration
Study: 33737646
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement
Study: 34088513
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic therapy with etoposide (50 mg, day 1 to 14) and cyclophosphamide (50 mg, day 1 to 28, every 4 weeks)
Study: 34088513
Drug: Pazopanib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (400 mg once daily) in addition to etoposide and cyclophosphamide
Study: 34088513
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic therapy with etoposide and cyclophosphamide
Study: 32766862
Drug: Direct to
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct to consumer referral pathway (e.g., digital and print media, registry emails)
Study: 32766862
Drug: Other referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other referral approaches (e.g., presentations, word of mouth)
Study: 33559816
Drug: Solution-oriented counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-oriented counseling
Study: 32389457
Drug: Self-injected subcutaneous
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-injected subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Study: 32389457
Drug: Provider-administered subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Study: 32389457
Drug: Self-injected and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injected and provider-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Study: 36178914
Drug: Traditional foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional foods index (measured as weekly servings of traditional food consumption divided by total foods reported)
Study: 33318391
Drug: Daily salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily salt intake estimated using the INTERSALT equation from morning spot urine samples.
Study: 33231866
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2 on days 1 and 8) + Pazopanib (800 mg daily)
Study: 33231866
Drug: Gemcitabine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (900 mg/m2 on days 1 and 8) + Docetaxel (100 mg/m2 on day 8)
Study: 34789450
Drug: CAL-assisted PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL-assisted PDT (calcipotriol applied daily for 15 days beforehand)
Study: 39265124
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of chemotherapy (ICC)
Study: 33432646
Drug: Rule-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rule-based treatment planning
Study: 34653732
Drug: Nanocurcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin (80 mg capsule daily for 8 weeks)
Study: 35302529
Drug: Motor imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor imagery + action observation therapy
Study: 35302529
Drug: Mixed therapy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed therapy (cognitive training + motor imagery + action observation therapy)
Study: 34374847
Drug: Hypnosis-derived communication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis-derived communication (HC) administered by trained nurses during outpatient chemotherapy.
Study: 33199422
Drug: Sodium selenate
Normalized name: Sodium Selenate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium selenate (15 mg three times a day)
Study: 35697435
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBGT)
Study: 35589674
Drug: Combined paracetamol-dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined paracetamol-dexamethasone
Study: 35338648
Drug: Restricted IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted IV fluid therapy
Study: 37330928
Drug: Standard IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IV fluid therapy
Study: 33538030
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (preservative free morphine sulfate, 0.09 mg/kg; 1% ropivacaine, 0.2 mg/kg; total volume delivered, 1 mL/4.5 kg of body weight to a maximum of 10 mL; n = 9)
Study: 32171875
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal therapy (Group I)
Study: 32171875
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal therapy combined with antimicrobial PDT (Group II)
Study: 33610421
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 gr/d for 10 weeks)
Study: 32282100
Drug: Vyxeos (daunorubicin-cytarabine)
Normalized name: Vyxeos
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vyxeos (daunorubicin-cytarabine) liposome injection
Study: 36294856
Drug: Erector Spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector Spinae Plane Block (ESPB) using 20 mL of 0.5% ropivacaine bilaterally
Study: 35244061
Drug: Bojungikgi-tang (BJT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bojungikgi-tang (BJT) granules administered twice a day for 8 weeks
Study: 35771533
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula/long-term oxygen therapy
Study: 34253233
Drug: 5-ALA HCl
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA HCl 15 mg/kg
Study: 34253233
Drug: 5-ALA HCl
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA HCl 30 mg/kg
Study: 32803636
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea supplements (1 g twice daily; containing 300 mg EGCG)
Study: 33822033
Drug: Spironolactone (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25-50 mg/day)
Study: 33797983
Drug: Delayed-Release and
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH)
Study: 33303428
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (1 to 3 sessions at intervals of one per week)
Study: 33303428
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (1 mL of Diprostène via ultrasound-guided injection)
Study: 35041046
Drug: Extruded rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extruded rice snacks containing 400 mg DHA from cauliflower-encapsulated HiDHA® algal oil
Study: 35041046
Drug: Soup containing
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soup containing 400 mg DHA from cauliflower-encapsulated HiDHA® algal oil
Study: 35041046
Drug: Gel capsules
Normalized name: Dried Aluminum Hydroxide Gel Capsules
DrugBank: Sepia esculenta bone (DB16562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel capsules containing HiDHA® algal oil
Study: 33046619
Drug: Mexiletine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (150 mg 3 times daily)
Study: 34148351
Drug: Apixaban or
Normalized name: apixaban Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban or rivaroxaban (direct acting oral anticoagulation)
Study: 32957929
Drug: Sufentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plasma target concentration 0.0 ng ml-1 (Group S0)
Study: 32957929
Drug: Sufentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plasma target concentration 0.1 ng ml-1 (Group S1)
Study: 32957929
Drug: Sufentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plasma target concentration 0.3 ng ml-1 (Group S2)
Study: 32957929
Drug: Sufentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plasma target concentration 0.5 ng ml-1 (Group S3)
Study: 32957929
Drug: Sufentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plasma target concentration 0.7 ng ml-1 (Group S4)
Study: 32229523
Drug: Accelerated partner
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated partner therapy (APT)
Study: 34337507
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group B)
Study: 33371995
Drug: Nurse Administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse Administered Propofol Sedation (NAPS)
Study: 33190147
Drug: Omega-3 carboxylic
Normalized name: omega-3 carboxylic acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 carboxylic acid (4 g/d)
Study: 38486192
Drug: Dignity Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity Therapy (DT)
Study: 33603939
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.375% ropivacaine with 100 ng of naloxone
Study: 34652445
Drug: β-lactam (amoxicillin-clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) for 5 extra days
Study: 32305106
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TXA
Study: 33685237
Drug: Pulsed high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed high-intensity laser therapy (HILT)
Study: 32799792
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.5 mg/kg intravenously
Study: 34085287
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM)
Study: 38485487
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhaled NO)
Study: 33512943
Drug: 3 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of radial extracorporeal shockwave therapy (rESWT) at the 'recommended'/'maximally comfortably tolerated' dose
Study: 33512943
Drug: 3 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of radial extracorporeal shockwave therapy (rESWT) at 'minimal dose'
Study: 33512943
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (recommended dose and minimal dose)
Study: 33512943
Drug: 3 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of rESWT (both doses)
Study: 35510753
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) combined with minocycline (100 mg per day for 8 weeks)
Study: 35510753
Drug: Minocycline only
Normalized name: Minocycline only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline only (100 mg per day for 8 weeks)
Study: 35893347
Drug: Scrambler Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrambler Therapy (ST)
Study: 36072252
Drug: Control (pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pain management drugs following the WHO analgesic ladder)
Study: 33120777
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with antidepressants
Study: 34287979
Drug: Glepaglutide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glepaglutide 0.1 mg and 1 mg
Study: 33721562
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks
Study: 34261908
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (7 days or less) after removal of the central venous catheter (CVC)
Study: 36369798
Drug: Deucravacitinib 3
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 3 mg twice daily
Study: 36369798
Drug: Deucravacitinib 6
Normalized name: deucravacitinib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 6 mg twice daily
Study: 39283417
Drug: Deucravacitinib 12
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 12 mg once daily
Study: 36369798
Drug: Deucravacitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib (all doses)
Study: 35714812
Drug: GSK3389404 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 (60 mg weekly)
Study: 35714812
Drug: GSK3389404 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 (120 mg weekly)
Study: 35714812
Drug: GSK3389404 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 (120 mg bi-weekly)
Study: 35714812
Drug: GSK3389404 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 (120 mg weekly, 120 mg bi-weekly)
Study: 32932891
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of Botulinum Toxin Type A (24 U)
Study: 32932891
Drug: Conventional blind
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional blind injection of Botulinum Toxin Type A (24 U)
Study: 34209804
Drug: Lacticaseibacillus paracasei
Normalized name: Lacticaseibacillus paracasei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacticaseibacillus paracasei strain Shirota (LcS) beverage (100 mL, 108 CFU/mL)
Study: 38263652
Drug: Subcutaneous iscalimab
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous iscalimab (3 mg/kg)
Study: 35952529
Drug: Dexamethasone IV
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone IV combined with 15 sessions of hyperbaric oxygen therapy (SS + HBOT)
Study: 33893799
Drug: BCG vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccination + oral polio vaccine (OPV) immediately upon admission
Study: 34973048
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PE and AR)
Study: 34632490
Drug: Furosemide 80
Normalized name: furosemide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 80 mg bolus
Study: 34049356
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no immunotherapy)
Study: 39392168
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase
Study: 32175662
Drug: Nicorandil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (2 mg injected into the coronary artery)
Study: 33952670
Drug: ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Study: 33952670
Drug: clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel (300 mg loading dose on day 1 followed by 75 mg daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Study: 37980467
Drug: RTS,S/AS01 malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 malaria vaccine
Study: 36224244
Drug: Active M1‐rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active M1‐rTMS (10 Hz for 10 daily treatments over 2 weeks)
Study: 33147621
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication (200/50 mg levodopa-benserazide)
Study: 33147621
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (OFF medication)
Study: 36461704
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm short implants
Study: 36461704
Drug: 11 mm
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11 mm long implants
Study: 32128718
Drug: After twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: After twice artificial abortion (ATAA)
Study: 33298154
Drug: Duloxetine, antivirals,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine, antivirals, and analgesics
Study: 33298154
Drug: Control (antivirals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antivirals and analgesics only)
Study: 34344428
Drug: Culture‐directed antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture‐directed antibacterial therapy based on percutaneous bone biopsy culture results
Study: 34344428
Drug: Culture‐directed antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture‐directed antibacterial therapy based on ulcer bed biopsy culture results
Study: 33860324
Drug: SNP selection
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNP selection strategy using a combination of mean minor allele frequency (MAF) and linkage disequilibrium (LD)
Study: 35491532
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg daily
Study: 33243277
Drug: Double Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Sequential External Defibrillation (DSED)
Study: 33704698
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of exercise training
Study: 33704698
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of exercise training
Study: 33020354
Drug: S One
Normalized name: Nestabs ONE
DrugBank: Calcium ascorbate (DB14483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S One Group II (used instruments after ex vivo treatment)
Study: 36074963
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 24% Su and LC 30 minutes before puncture
Study: 32403367
Drug: Glucose-based TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based TPN (group G)
Study: 32403367
Drug: Lipid-based TPN
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based TPN (group L)
Study: 32248227
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (NMES, TENS, NMES/TENS)
Study: 32697484
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395)
Study: 34351368
Drug: Less-intensive therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intensive therapies
Study: 34351368
Drug: Intensive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapies
Study: 32180692
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving an alternative meal (e.g. chicken, pork, and beef)
Study: 33349280
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBT-I); 8 sessions
Study: 33730722
Drug: Ginseng (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (twice daily for 4 weeks)
Study: 35726506
Drug: Oral Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Isotretinoin
Study: 33310418
Drug: eculizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: eculizumab (1200 mg/2 weeks)
Study: 32460799
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (self-administered test of alcohol use and advice regarding usual treatment in Estonia)
Study: 34424995
Drug: Colloid-based priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid-based priming solution (dextran 40)